Jiangsu Recbio Technology Co., Ltd. (HKG:2179)
5.00
0.00 (0.00%)
Sep 4, 2026, 9:15 AM HKT
Jiangsu Recbio Technology Revenue
Jiangsu Recbio Technology had revenue of 7.50M CNY in the half year ending June 30, 2026, a decrease of -57.46%. This brings the company's revenue in the last twelve months to 492.00K, down -98.31% year-over-year. In the year 2025, Jiangsu Recbio Technology had annual revenue of 12.73M.
Revenue (ttm)
492.00K CNY
Revenue Growth
-98.31%
P/S Ratio
5,321.09
Revenue / Employee
1.06K CNY
Employees
466
Market Cap
3.02B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.73M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 30.38M | 25.05M | 470.46% |
| Dec 31, 2022 | 5.33M | -874.00K | -14.10% |
| Dec 31, 2021 | 6.20M | 4.74M | 325.17% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Viva Biotech Holdings | 2.20B |
| Frontage Holdings | 2.18B |
| Qyuns Therapeutics | 1.18B |
| Medtide | 635.93M |
| BioDlink International Company | 582.45M |
| Laekna | 296.69M |
| Mirxes Holding Company | 166.32M |
| TransThera Sciences (Nanjing) | 40.93M |